Fortitude Family Office’s Fulgent Genetics FLGT Stock Holding History

Fortitude Family Office’s Portfolio FLGT Stock Details FLGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-26	Closed	-$517	–	2038
2025 Q2	$517	Buy	+26	New	+$507	﹤0.01%	1795

Other funds holding FLGT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Fortitude Family Office's FLGT Position: Q3 2025 in Review

Fortitude Family Office sold out of Fulgent Genetics (FLGT) in Q3 2025, closing a stake of 26 shares — an estimated $517 sold.

Fortitude Family Office first reported a position in FLGT in Q2 2025 and held it in 1 quarter. The position peaked at $517 in Q2 2025. 163 funds tracked by Wall St. Rank hold FLGT as of Q3 2025.

Fortitude Family Office reported no remaining Fulgent Genetics position as of Q3 2025 after selling out during the quarter.
Fortitude Family Office sold 26 Fulgent Genetics shares in Q3 2025, an estimated $517.
Fortitude Family Office first reported a position in Fulgent Genetics in Q2 2025 and held it in 1 quarter.
Fortitude Family Office's Fulgent Genetics position peaked at $517 in Q2 2025.
163 funds tracked by Wall St. Rank held Fulgent Genetics as of Q3 2025.

Based on Fortitude Family Office's 13F filing for Q3 2025, filed 17 Oct 2025.